DVA
DaVita Inc.Healthcare · $11.5B market cap
Verdict
Share price
$178.69
close of Oct 3, 2026
Fair value
$106.00
Sticker Price
Payback Price
$42.40
buy price
DVA is Overpriced: at $178.69 it trades 69% above its fair value of $106.00. Its buy price (Payback Price) is $42.40, 76% below today's price. Business quality is limited: only 1 of 5 key numbers clears the 10% bar.
How we valued it
Free Cash Flow Growth. Free cash flow is growing faster than reported earnings, so we project free cash flow 10 years ahead instead.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow DVA
Get notified when it reaches its buy price of $42.40. Free.
Create a free accountSuperinvestors
1 of the investors we track holds DVA. Who we track
Insider activity
Since Jun 15, 2026: no open-market purchases, 5 sales worth $54.3M and 8 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
BERKSHIRE HATHAWAY INC
Owns 10%+ · 2026-07-31
Sold
$36.5M
Rodriguez Javier
Chief Executive Officer · 2026-06-16
Sold
$8.2M
Rodriguez Javier
Chief Executive Officer · 2026-06-15
Sold
$6.3M
Waters Kathleen Alyce
Chief Legal & Pub. Affairs Off · 2026-06-15
Sold
$1.4M
Waters Kathleen Alyce
Chief Legal & Pub. Affairs Off · 2026-06-15
Sold
$1.9M
Other filings
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic…
Medical - Care Facilities
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works